← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 1, 2008Last known activity
Mar 22, 2023
Timeline
1910s
- Jun 1, 1914
Daegu Catholic University— Founded
Drugs by trial phase (44 distinct, 28 trials)
Phase 4 (12 own, 0 via acquisition)
Phase 3 (18 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (9 own, 0 via acquisition)
Indications
Studied for
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Diabetic Neuropathies
- Dyspepsia
- Essential Hypertension
- Heart Failure
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Hypertension
- Invasive Fungal Infections
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Chronic-Phase
- Mycoses
- Myelodysplastic Syndromes
- Neuralgia
- Pancreatic Neoplasms
- Spondylitis
- Spondylitis, Ankylosing
- Stomach Neoplasms
- Urinary Bladder, Neurogenic
- Wounds and Injuries
Recent trials (39)
- NCT05774366Reponsible party - principal investigatorN/AMar 22, 2023
- NCT05774366Lead sponsorN/AMar 22, 2023
- NCT05774366Overall official - principal investigatorN/AMar 22, 2023
- NCT05635201Lead sponsorPhase 3Dec 19, 2022
- NCT05635201Overall official - principal investigatorPhase 3Dec 19, 2022
- NCT05635201Reponsible party - principal investigatorPhase 3Dec 19, 2022
- NCT05493631Overall official - principal investigatorPhase 1Aug 24, 2022
- NCT06081803CollaboratorPhase 3Dec 5, 2020
- NCT04466046Study chairN/ASep 4, 2019
- NCT04466046Reponsible party - principal investigatorN/ASep 4, 2019
- NCT04466046Lead sponsorN/ASep 4, 2019
- NCT03487003Reponsible party - principal investigatorN/AApr 20, 2018
- NCT03487003Lead sponsorN/AApr 20, 2018
- NCT03487874Overall official - principal investigatorN/AApr 4, 2018
- NCT03487874Lead sponsorN/AApr 4, 2018
Details
- Founded
- Yeongnam, KR Jun 1, 1914
- Last known activity
- Mar 22, 2023